Alterity Therapeutics Limited (ATHE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Alterity Therapeutics Limited (ATHE) is up 60.1% since the beginning of the year. At $5 per share, ATHE is trading 29.6% below its 52-week high of $7. Investors who bought $1,000 worth of ATHE shares 5 years ago would now be looking at an investment worth $376.

Alterity Therapeutics Limited (ATHE) has returned 60.06% so far this year and 17.38% over the past 12 months. Over the last ten years, ATHE has returned -20.15% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Sep 5, 2002, ATHE's average daily return is +0.12%, while the average monthly return is +0.55%. At this rate, an investment would double in approximately 10.5 years.

Historically, 43% of months were positive and 57% were negative. The best month was Dec 2024 with a return of +134.8%, while the worst month was Mar 2014 at -75.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 11 months.

On a daily basis, ATHE closed higher 42% of trading days. The best single day was Aug 4, 2020 with a return of +154.1%, while the worst single day was Mar 31, 2014 at -71.6%.

Alterity Therapeutics Limited has an annualized alpha of 29.55%, beta of 0.40, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 05, 2002.

• This stock participated in 126.02% of S&P 500 Index downside but only 1.84% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.40 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ATHE ranks 51 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Alterity Therapeutics Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alterity Therapeutics Limited was 99.86%, occurring on Nov 20, 2024. The portfolio has not yet recovered.

The current Alterity Therapeutics Limited drawdown is 99.36%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Alterity Therapeutics Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Alterity Therapeutics Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.